Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878084 | 1.00 | BACE1 (0.38) | BACE1CTSDNQO2 | |
| SCHEMBL892224 | 0.92 | BACE1 (0.48) | BACE1 | |
| SCHEMBL892255 | 0.84 | PDE7A (0.38) | — | |
| SCHEMBL891892 | 0.79 | BACE1 (0.51) | BACE1CTSD | |
| SCHEMBL875232 | 0.68 | BCHE (0.47) | — | |
| SCHEMBL891684 | 0.65 | BACE1 (0.49) | BACE1CTSD | |
| SCHEMBL12747304 | 0.63 | BACE1 (0.82) | BACE1 | |
| SCHEMBL12827639 | 0.62 | BACE1 (0.85) | BACE1 | |
| SCHEMBL12746214 | 0.62 | BACE1 (0.61) | BACE1 | |
| SCHEMBL10209616 | 0.62 | BACE1 (0.70) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | BACE1 1/4885CTSD 224/4885NQO2 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.